Laura Deming: I’m very interested in the tradeoff and relation between investing more in basic science (with the goal of major theoretical breakthroughs) and developing technology and products (which can have immediate impact but perhaps not as important in the long term).
For example,
1. What is the role of the Academia in progress on aging, as opposed to private research groups? In general, how much resources do they have and what are they incentivized to?
2. What are the current bottlenecks in longevity research and tech?
3. How do you view the market and general public view of longevity in the near future?
Laura Deming: I’m very interested in the tradeoff and relation between investing more in basic science (with the goal of major theoretical breakthroughs) and developing technology and products (which can have immediate impact but perhaps not as important in the long term).
For example,
1. What is the role of the Academia in progress on aging, as opposed to private research groups? In general, how much resources do they have and what are they incentivized to?
2. What are the current bottlenecks in longevity research and tech?
3. How do you view the market and general public view of longevity in the near future?